Last reviewed · How we verify
NCT03407768: MyCHOICE
Role of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast Cancer
NA trial testing Individualized interventions in Breast Cancer in 41 participants. Completed in 30 November 2024.
30 November 2024
Quick facts
| Lead sponsor | University of Saskatchewan |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 41 |
| Start date | 1 July 2018 |
| Primary completion | 30 November 2024 |
| Estimated completion | 30 November 2024 |
| Sites | 2 locations across Canada |
Drugs / interventions tested
- Individualized interventions
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Premenopausal Breast Cancer — all drugs for Premenopausal Breast Cancer →
- Hormone Receptor Positive Tumor — all drugs for Hormone Receptor Positive Tumor →
Sponsor
University of Saskatchewan
Who can join
Eligibility, female only, with Breast Cancer or Premenopausal Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Although combination endocrine therapy has been associated with significant reduction in risk of recurrence in younger women with hormone receptor positive breast cancer, it has been associated with more adverse effects and decline in quality of life (QOL). Various behavioral and complementary interventions can be effective in reducing treatment-related side effects. The study aims to evaluate if individually-tailored behavioral and complementary interventions could improve treatment tolerance and adherence in women with early stage breast cancer. This benefit will be assessed primarily by change in QOL and secondarily by adherence to adjuvant endocrine treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03407768
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other University of Saskatchewan trials
Trials by the same sponsor.
- NCT07433686 — Saskatoon Berry Juice for Muscle Recovery · NA · not yet recruiting
- NCT07489469 — Effectiveness of an AI Scribe Compared to Routine Templates for Clinical Documentation in Orthopedic Consultations · NA · completed
- NCT06946316 — Dairy vs Plant-based Beverages for Improving Bone Health During Exercise · NA · recruiting
- NCT04276857 — Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer · NA · recruiting
- NCT03401294 — Conversion From Unresectable To Resectable Metastatic Colorectal Cancer. · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03407768 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Saskatchewan
- Last refreshed: 5 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03407768.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing